mm-111 + lapatinib + paclitaxel + trastuzumab

MM-111 + lapatinib + paclitaxel + trastuzumab is a **combination drug regimen** investigated primarily in HER2-positive cancers, notably gastroesophageal and breast cancers. **MM-111** is a bispecific antibody fusion protein that simultaneously targets **ERBB2 (HER2)** and **ERBB3 (HER3)**, forming an inactive receptor complex and suppressing HER3-dependent signaling pathways, thus inhibiting cell proliferation. **Trastuzumab** is a monoclonal antibody that binds to HER2 and blocks downstream cell proliferation pathways. **Lapatinib** is a small molecule inhibitor of both HER2 and EGFR tyrosine kinases, disrupting cellular signaling. **Paclitaxel** is a cytotoxic chemotherapeutic agent that stabilizes microtubules to prevent cell division. The combination aims to provide synergistic inhibition of HER2/HER3 signaling, block compensatory resistance mechanisms, and maximize tumor cell death. Clinical studies show that, although this combination can be more effective than individual agents, some trials in HER2+ gastroesophageal cancer found that adding MM-111 to paclitaxel and trastuzumab resulted in lower survival, leading to early termination of such trials[2][3][4].

Brand names

TykerbHerceptinTaxol